Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Botulinum toxin type a in rat model of peripheral neuropathy (CROSBI ID 502629)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa

Bach-Rojecky, Lidija ; Relja, Maja ; Lacković, Zdravko Botulinum toxin type a in rat model of peripheral neuropathy // Journal of neural transmission / Riederer, Peter (ur.). 2004. str. 46-46

Podaci o odgovornosti

Bach-Rojecky, Lidija ; Relja, Maja ; Lacković, Zdravko

engleski

Botulinum toxin type a in rat model of peripheral neuropathy

Over the last 20 years BTX-A has been used for treating a variety of disorders characterized by increased muscle contraction and recently few clinical observations on several patients indicated that it might be useful in neuropathic pain. However up to now preclinical nociceptive action of BTX-A has been investigated in only few studies employing formalin and capsaicin tests. Here we report on the efficacy of BTX-A in rat models of neuropathic pain. After dose-response and time-course experiments performed with BTX-A using formalin and carrageenan to provoke acute pain associated with inflammation, the effectiveness of BTX-A on chronic neuropathic pain was tested. Peripheral neuropathy was evoked by partial sciatic nerve transection. Animals which developed neuropathic pain showed increased sensitivity to thermal and mechanical stimuli and were included in further investigation and treated with BTX-A. The results of present experiments show that peripherally administered BTX-A produces analgesic effect in formalin test that seems not to be clearly dose-dependent. The analgesic effect becomes significant on day 5 following toxin’s application in the rat paw pad and lasts for 30 days. However, peripherally applied BTX-A has also found to be effective in peripheral neuropathy reducing the enhanced sensitivity to pain stimuli. This study, for the first time, in experimental animals demonstrated the efficacy of BTX-A in treating experimental peripheral neuropathic pain.

botulinum toxin; pain; nociception

doi: 10.1007/s00702-004-0132-0

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

46-46.

2004.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Journal of neural transmission

Riederer, Peter

Beč: Springer

0300-9564

Podaci o skupu

Congress of the European Society for Clinical Neuropharmacology /7 ; 2004)

poster

05.05.2004-09.05.2004

Trst, Italija

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost